AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD). 

Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).

CLEAR OUTCOMES is a double-blind, randomized, placebo-controlled trial, where statin-intolerant patients who have or are at high risk for cardiovascular disease, including PAD, received once-daily tablets of either bempedoic acid or placebo. 13,970 patients were enrolled in the trial and were followed-up for a duration of 68 months. The primary outcome measure was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or coronary revascularization. 

Interview Questions:
1.    What is the reasoning behind the CLEAR OUTCOMES trial?
2.    Could you tell us about the mechanism of action behind bempedoic acid?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.